GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Revenue

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Revenue : NT$4.85 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Revenue?

Great Novel Therapeutics Biotech & Medicals's revenue for the six months ended in Dec. 2023 was NT$0.09 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was NT$4.85 Mil. Great Novel Therapeutics Biotech & Medicals's Revenue per Share for the six months ended in Dec. 2023 was NT$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was NT$0.14.

During the past 12 months, the average Revenue per Share Growth Rate of Great Novel Therapeutics Biotech & Medicals was 545.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 6 years, Great Novel Therapeutics Biotech & Medicals's highest 3-Year average Revenue per Share Growth Rate was 49.40% per year. The lowest was -51.60% per year. And the median was -1.10% per year.


Great Novel Therapeutics Biotech & Medicals Revenue Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Revenue Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial 0.09 - 0.63 0.54 4.85

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.54 - 4.76 0.09

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's Revenue

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Great Novel Therapeutics Biotech & Medicals's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Revenue distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Revenue falls into.



Great Novel Therapeutics Biotech & Medicals Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$4.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Great Novel Therapeutics Biotech & Medicals Revenue Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines